Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary
for their growth. The Epstein Barr virus can cause cancer and lymphoproliferative disorders.
Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Giving ganciclovir
together with bortezomib may kill more Epstein Barr virus-infected cancer cells.
PURPOSE: This clinical trial is studying how well giving bortezomib together with ganciclovir
works in treating patients with relapsed or refractory Epstein Barr virus-positive lymphoma.